Centre Technology Transfer CITTRU

A diagnostic test of Streptococcus agalactiae infections in pregnant women.

Posted by Centre Technology Transfer CITTRUResponsive · Innovative Products and Technologies · Poland

Summary of the technology

Rapid diagnosis of infections caused by GBS guarantees the immediate implementation of antibiotic therapy. However, there are currently no diagnostic tests that allow confirmation of infections caused by S. agalactiae. Previous diagnostic methods traditionally used in carriage of S. agalactiae are based on method of cultivation (the so-called „gold standard”), which has a low sensitivity and a long time (up to several days) to wait for result. The another approach are metods of molecular biology, including methods for real-time PCR, which allow to obtain a result in a short time. However they are very expensive and they also require the use of special equipment. The proposed new test uses four highly immunoreactive amino acid sequences belonging to proteins of S. agalactiae. It shows a high sensitivity and specificity. The results of this test are obtained in a short time (up to 8 hours). One of the most important features of new test is the lack of special equipment to carry out a new diagnostic test. The proposed test may confirm the Streptococcus agalactiae infections in pregnant women. There is the possibility to extend the application of diagnostic test for detection of infections based on GBS etiology in other patient groups (e.g. infants, outpatients and hospital patients) and using other clinical materials (plasma, cerebrospinal fluid).

Description of the technology

The offer is a new diagnostic test which may confirm the Streptococcus agalactiae infections in pregnant women. The proposed test uses a specific reaction of immunoreactive proteins derived from clinical isolates of S. agalactiae with the antibodies present in serum of patients, and thus it provides an alternative to commonly used solutions in this field.

Specifications

The offered invention relates to a new diagnostic test which may confirm the Streptococcus agalactiae infections in pregnant women. The proposed test uses a specific reaction of immunoreactive proteins derived from clinical isolates of S. agalactiae with serum antibodies of patients, and provides an alternative to the currently used solutions in this field.

Main advantages of its use

  • A target group includes all pregnant women
  • High sensitivity and specificity
  • No need for special equipment – application in all analytical and microbiological laboratories
  • Short duration of the assay (up to 8 hours)
  • The possibility to extend the application of diagnostic test for detection of infections based on GBS etiology in other patient groups (e.g. infants, outpatients and hospital patients) and using other clinical materials (plasma, cerebrospinal fluid).
  • The use of four highly immunoreactive amino acid sequences belonging to proteins of S. agalactiae

Applications

  • The bacteria of Streptococcus agalactiae, classified as serogroup B of streptococci (called group B Streptococcus, GBS) colonize the lower intestinal tract, anus and vagina without causing any symptoms during the infection. It was confirmed that GBS is found most frequently in vagina and rectum at approximately 10-30% of pregnant women. Colonization may be temporary, chronic or intermittent. However, the presence of group B streptococci in vagina during pregnancy is an important risk factor for infection in newborns. Rapid diagnosis of infections caused by GBS guarantees the immediate implementation of antibiotic therapy. The proposed innovative test allows confirmation of infections caused by S. agalactiae and thus it finds an application in the biomedical field.

Related keywords

  • Microbiology Technology
  • Gynaecology
  • Microbiology Market
  • Streptococcus agalactiae
  • sepsis
  • diagnostic test
  • infection
  • pregnant women
  • bacteria

About Centre Technology Transfer CITTRU

Technology Transfer Office from Poland

Centre for Innovation, Technology Transfer and University Development (CITTRU) is a part of Jagiellonian University, whose role is to promote university research, to support innovation and to create cooperation with the business. CITTRU main task is to offer the scientific achievements of the Jagiellonian University in the market by providing legal protection, licensing, sale of intellectual property rights, creation of academic business, coordination of company-ordered research projects, etc. Currently promoted technologies are mainly focused on new materials science, pharmacology and medical technology. Inventions offered by Jagiellonian University are promoted and awarded during numerous exhibitions, e.g. 58th International Exhibition of Innovation, Research and New Technologies INNOVA (BRUSSELS 2009), 38th International Exhibition of Invention New Techniques & Products (Geneva 2010) or 24th International exhibition of environmental equipment, technologies and services POLLUTEC (Paris 2009).

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.